M&A

Move Over Boston Sci, Hologic Is on an M&A Hot Streak Too
Medical Devices and Diagnostics Industry
Fri, 10/15/21 - 10:36 pm
Medtech
devices
Hologic
M&A
Bolder Surgical
Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention
BioSpace
Thu, 10/14/21 - 11:12 pm
Merck
Acceleron
M&A
Bristol Myers Squibb
Aceto makes further inroads into biopharma space, buys up A&C Bio Buffer
Biopharma Reporter
Wed, 10/13/21 - 11:01 am
Aceto
A&C Bio Buffer
M&A
drug manufacturing
vaccines
Europe
Charles River Laboratories has been on an acquisition spree. But Tuesday, it offloaded two assets
Endpoints
Wed, 10/13/21 - 10:53 am
Charles River Laboratories
M&A
gene therapy
CDMOs
Bionano frames $90M BioDiscovery buy as way to expand genomics analysis
MedCity News
Wed, 10/13/21 - 10:45 am
Bionano Genomics
M&A
BioDiscovery
genomics
software
Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180
Fierce Pharma
Tue, 10/12/21 - 11:35 pm
Merck
Pharma CEOs
Robert Davis
M&A
Acceleron
Flexion heads to the discount aisle for a $450M+ merger with Pacira
Endpoints
Mon, 10/11/21 - 10:18 am
Flexion
M&A
Pacira
Supernus expands its portfolio of Parkinson's drugs with a $400M+ buyout
Endpoints
Mon, 10/11/21 - 10:08 am
Supernus
Parkinson's Disease
M&A
Adamas Pharmaceuticals
Medtechs opened 2021 with a flurry of M&A and have not stopped spending since
Medtech Dive
Fri, 10/8/21 - 10:55 am
devices
Medtech
M&A
Boston Scientific
Baylis Medical
GE Healthcare
BK Medical
Devoro Medical
Philip Morris
Vectura
Is an Acquisition of Acceleron a Smart Move for Merck?
Motley Fool
Fri, 10/8/21 - 10:35 am
Merck
M&A
Acceleron
PAH
Keytruda
AstraZeneca’s Alexion concludes Caelum acquisition for $500m
Pharmaceutical Business Review
Thu, 10/7/21 - 11:22 am
AstraZeneca
Alexion
Caelum Biosciences
M&A
Biopharma needs a biggie to avoid a down deal year
EP Vantage
Thu, 10/7/21 - 11:07 am
M&A
Merck
Acceleron
Sanofi
Translate Bio
Amgen
Teneobio
Pfizer
Trillium
Perrigo
HRA Pharma
Biogen, mRNA players on Merck's M&A radar as CEO still hungry for deals after $11.5B Acceleron buy: FT
Fierce Pharma
Wed, 10/6/21 - 11:26 pm
Merck
M&A
Biogen
Mirati Therapeutics
Boston Scientific inks $1.75B deal for Baylis, biggest in string of M&A
Medtech Dive
Wed, 10/6/21 - 10:39 am
devices
M&A
Boston Scientific
Baylis Medical
Trouble builds for Merck's $11.5B Acceleron buy as activist investor behind Gilead's Immunomedics deal says too early, too cheap
Fierce Pharma
Fri, 10/1/21 - 10:55 am
Merck
Acceleron
M&A
investors
Avoro Capital
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema
Pharmaforum
Fri, 10/1/21 - 10:48 am
Sanofi
eczema
M&A
Kymab
KY1005
clinical trials
Merck & Co justifies paying up for Acceleron
EP Vantage
Fri, 10/1/21 - 10:46 am
Merck
Accleron
M&A
sotatercept
Reblozyl
PAH
Pharma CEO confidence tops pre-pandemic levels, companies look to nucleic-acid technology assets to fuel growth
Biopharma Reporter
Thu, 09/30/21 - 10:54 am
Pharma CEOs
biotech
M&A
confidence
Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug
BioSpace
Thu, 09/30/21 - 12:01 am
Merck
Acceleron
M&A
PAH
Amicus Splits into Two as FDA Sets PDUFA for Pompe Disease Treatment
BioSpace
Wed, 09/29/21 - 11:56 pm
Amicus Therapeutics
Pompe disease
Caritas Therapeutics
M&A

Pages